Cantor Fitzgerald analyst Charles Duncan raised his price target for Axsome Therapeutics to $16 from $13 following the company’s Q4 results. The analyst sees multiple potentially stock-moving milestones coming up for Axsome and keeps an Overweight rating on the shares.
https://thefly.com/landingPageNews.php?id=2879815
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.